All Oncology News

Low disease burden prior to treatment with CD19-specific chimeric antigen receptor T-cell therapy appears to be a positive prognostic factor for long-term survival outcomes of patients with relapsed B-cell acute lymphoblastic leukemia.

A novel target, B-cell maturation antigen, has been identified for future therapeutic development as chimeric antigen receptor T-cell therapy for patients with multiple myeloma.

The real impetus for fueling the Cancer Moonshot is coming from community oncology practices, not large research institutions, according to the Community Oncology Alliance.

Veliparib failed to meet the primary endpoint in phase III non-small cell lung cancer and triple-negative breast cancer trials.

Matthew B. Yurgelun, MD, discusses a study that determined that nearly 10% of patients with colorectal cancer had germline cancer susceptibility gene mutations and its implications for patients and their families.

C. Kent Osborne, MD, sheds light on the current and future treatment of HER2-positive breast cancer.

Consolidation therapy with lenalidomide, bortezomib, and dexamethasone (RVD), when used in conjunction with stem cell transplantation, extended progression-free survival compared with RVD alone in patients with multiple myeloma.

Sophie Papa, MD, discusses the early-phase results and the logic behind studying CAR T-cell therapy in solid tumors, such as head and neck cancer.

There is no comprehensive, multidisciplinary guideline document for the screening, management, and long-term care of myeloma patients. The UK Myeloma Forum and the British Society for Haematology set out to address this need and published such a guideline in a recent issue of the British Journal of Hematology.

Patients with chronic lymphocytic leukemia who stopped treatment with ibrutinib (Imbruvica) for toxicities had longer survival than those who discontinued for other reasons, including progression and Richter transformation.

Julie R. Brahmer, MD, discusses the 5-year findings of nivolumab in non-small cell lung cancer, their significance, and expected next steps for this research.

The FDA has granted a breakthrough therapy designation to tisagenlecleucel-T (CTL019) for use as a treatment for adult patients with relapsed/refractory diffuse large B-cell lymphoma after the failure of at least 2 prior therapies.

The FDA has granted an accelerated approval to atezolizumab as a frontline treatment for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

The FDA has scheduled an Oncologic Drugs Advisory Committee hearing for May 24, 2017, to discuss a new drug application for neratinib as a treatment for patients with HER2-positive breast cancer following prior treatment with postoperative trastuzumab, according to a statement from the developer of the TKI, Puma Biotechnology.

Sukhmani Padda, MD discusses the status of ongoing clinical trials participating in this race to the frontline setting in lung cancer.

Steven H. Lin, MD, PhD discusses the benefits of advanced radiation technologies, including intensity-modulated radiation therapy and proton therapy, specifically for patients with esophageal cancer.

Lyndsay J. Willmott, MD, highlights the FDA-approved PARP inhibitors for ovarian cancer and how these approvals have impacted clinical practice.

Robert Dreicer, MD, highlights several emerging treatments for patients with metastatic castration-resistant prostate cancer.

Steven J. Katz, MD, discusses his study of patient reaction to surgeon recommendations about contralateral prophylactic mastectomy for patients with breast cancer.

Mike Janicek, MD sheds light on why physicians are slow to educate patients on testing, the detection of genes aside from BRCA1/2, and the lesser-known benefits of getting genetic testing early on in a diagnosis.

The FDA has eliminated the need for risk evaluation and mitigation strategy certification prior to the administration of erythropoiesis-stimulating agents for anemia due to myelosuppressive chemotherapy.

Nathan Fowler, MD, discusses the current management of high-risk follicular lymphoma and ongoing developments in the field.

Shlomo Koyfman, MD, discusses the findings of a recent study of patients with HPV-positive oropharyngeal cancer treated with cisplatin-based chemoradiotherapy or cetuximab-based bioradiotherapy.

Researchers concluded that survivors of Ewing sarcoma are largely free of physical limitations and there is little apparent difference between survivors and healthy people in terms of mental health.

Dana Chase, MD, expands on the pivotal clinical trials, managing toxicities, and the questions researchers still need to answer regarding bevacizumab for patients with ovarian cancer.

John L. Marshall, MD, discusses the results of the CALGB 80405 trial and other ongoing efforts to determine the underlying molecular basis for the sidedness issue in colorectal cancer.

Dhanya Nambiar, PhD, discusses the role of galectin-1 in the tumor microenvironment, and the potential for targeting this protein in patients with head and neck cancer.

The presence of androgen receptor splice variant-7 (AR-V7) mRNA in circulating tumor cells predicted poorer outcomes for men with castration-resistant prostate cancer assigned to novel hormonal therapies, according to results recently published in the Journal of Clinical Oncology.

Frederick L. Locke, MD, discusses the ZUMA-1 trial in non-Hodgkin lymphoma and the next steps going forward.

A set of draft recommendations for controlling price escalation in the Medicare Part B program has ignited fresh concern from the oncology community, which battled last year to overcome the Medicare Part B Drug Payment Model cost reduction experiment.